FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)GlobeNewsWire • 02/07/24
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 01/25/24
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary BreakthroughsInvestorPlace • 01/23/24
Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a BetZacks Investment Research • 12/05/23
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin ProgramsGlobeNewsWire • 11/28/23
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/14/23
Alector Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/23
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)GlobeNewsWire • 10/27/23
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to TradeZacks Investment Research • 08/10/23
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/06/23
Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?Zacks Investment Research • 05/09/23
Alector Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/23
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/27/23